Cantor Fitzgerald set a $160.00 price objective on Celgene Corporation (NASDAQ:CELG) in a research note released on Thursday morning. The firm currently has a buy rating on the biopharmaceutical company’s stock.

A number of other research analysts have also issued reports on CELG. Cann restated a buy rating and set a $148.00 price objective on shares of Celgene Corporation in a research report on Tuesday, April 4th. Oppenheimer Holdings, Inc. restated an outperform rating and set a $148.00 price objective on shares of Celgene Corporation in a research report on Wednesday, April 5th. Jefferies Group LLC restated a buy rating and set a $154.00 price objective on shares of Celgene Corporation in a research report on Tuesday, April 11th. Robert W. Baird restated an outperform rating and set a $162.00 price objective on shares of Celgene Corporation in a research report on Wednesday, April 19th. Finally, Barclays PLC restated an equal weight rating and set a $125.00 price objective (up previously from $120.00) on shares of Celgene Corporation in a research report on Sunday, April 23rd. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and twenty-two have given a buy rating to the stock. Celgene Corporation currently has a consensus rating of Buy and an average target price of $143.61.

Shares of Celgene Corporation (CELG) opened at 134.10 on Thursday. Celgene Corporation has a 1-year low of $96.93 and a 1-year high of $139.00. The stock’s 50 day moving average price is $131.06 and its 200 day moving average price is $122.99. The stock has a market cap of $104.71 billion, a PE ratio of 41.53 and a beta of 1.89.

Celgene Corporation (NASDAQ:CELG) last released its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $1.82 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.61 by $0.21. Celgene Corporation had a return on equity of 68.51% and a net margin of 21.35%. The business had revenue of $3.27 billion during the quarter, compared to analyst estimates of $3.23 billion. During the same quarter in the previous year, the firm posted $1.44 EPS. The business’s revenue for the quarter was up 18.7% compared to the same quarter last year. On average, equities research analysts anticipate that Celgene Corporation will post $7.32 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Celgene Corporation (NASDAQ:CELG) PT Set at $160.00 by Cantor Fitzgerald” was originally posted by Watch List News and is owned by of Watch List News. If you are viewing this story on another publication, it was stolen and republished in violation of U.S. & international trademark and copyright law. The correct version of this story can be viewed at https://www.watchlistnews.com/celgene-corporation-nasdaqcelg-pt-set-at-160-00-by-cantor-fitzgerald/1463405.html.

In related news, Director Michael D. Casey sold 9,250 shares of the company’s stock in a transaction on Monday, June 19th. The stock was sold at an average price of $125.59, for a total transaction of $1,161,707.50. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director James J. Loughlin sold 18,500 shares of the company’s stock in a transaction on Monday, June 26th. The shares were sold at an average price of $133.57, for a total value of $2,471,045.00. Following the transaction, the director now directly owns 32,877 shares in the company, valued at $4,391,380.89. The disclosure for this sale can be found here. Insiders have sold 227,755 shares of company stock worth $30,368,142 over the last three months. 0.95% of the stock is owned by insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of CELG. Diversified Trust Co increased its stake in shares of Celgene Corporation by 0.4% in the first quarter. Diversified Trust Co now owns 2,342 shares of the biopharmaceutical company’s stock valued at $291,000 after buying an additional 9 shares in the last quarter. Sowell Financial Services LLC increased its stake in shares of Celgene Corporation by 0.5% in the first quarter. Sowell Financial Services LLC now owns 2,454 shares of the biopharmaceutical company’s stock valued at $289,000 after buying an additional 13 shares in the last quarter. South Texas Money Management Ltd. increased its stake in shares of Celgene Corporation by 0.6% in the first quarter. South Texas Money Management Ltd. now owns 2,453 shares of the biopharmaceutical company’s stock valued at $305,000 after buying an additional 15 shares in the last quarter. Flagship Harbor Advisors LLC increased its stake in shares of Celgene Corporation by 0.9% in the first quarter. Flagship Harbor Advisors LLC now owns 2,054 shares of the biopharmaceutical company’s stock valued at $253,000 after buying an additional 18 shares in the last quarter. Finally, Keel Point LLC increased its stake in shares of Celgene Corporation by 0.9% in the first quarter. Keel Point LLC now owns 3,103 shares of the biopharmaceutical company’s stock valued at $386,000 after buying an additional 28 shares in the last quarter. 78.39% of the stock is currently owned by hedge funds and other institutional investors.

About Celgene Corporation

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Analyst Recommendations for Celgene Corporation (NASDAQ:CELG)

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.